Skip to main content
SpringerLink
Log in

Glycaemic variability and inflammation in subjects with metabolic syndrome

  • Original Article
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

Abstract

Subjects who develop diabetes have an increased cardiovascular risk even before the appearance of diabetes. The aim of this study was to investigate the glycaemic variability measured by continuous glucose monitoring (CGM CV%) in nondiabetic subjects with metabolic syndrome (MS) and to explore if glycaemic variability was associated with circulating levels of interleukin-6 (IL-6), a proinflammatory cytokine, or with an anti-inflammatory factor like adiponectin. Three groups of obese subjects with (MS+: 6m, 8f; BMI 33.1 ± 1.4 mean ± SEM) or without metabolic syndrome (MS−: 2m, 4f; BMI 29.2 ± 2.2) and with MS associated with type 2 diabetes (MS/T2D: 3m, 5f; BMI 32.9 ± 1.4) were investigated. The glycaemic variability was measured in all subjects in terms of CV% of the glycaemic values obtained every 3 min during the course of a 48 h CGM performed using a subcutaneous glucose sensor. The average CGM CV% increased from MS− group (21.1%) to the MS+ group (23.9%) and to the MS+/T2D group (27.4%) but it was not correlated to the CGM mean glycaemia (r = 0.20; P = ns). In some instances, CGM CV% was found higher in MS+ subjects than in some MS+ T2D ones. Stepwise multiple correlation analysis showed that IL-6 predicted CGM CV% (R 2 = 0.35, β = 0.13; P < 0.05) independently from BMI, waist circumference, adiponectin and insulin concentrations. In conclusion, the CGM CV% may contribute to better describe the individual metabolic state and to understand the pathogenesis of endothelial dysfunction in non diabetic subjects with MS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Wright E, Scism-Bacon JL, Glass LC (2006) Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract 60:308–314

    Article  PubMed  CAS  Google Scholar 

  2. Haffner SM, Stern MP, Mazuda HP, Mitchell BD, Patterson JK (1990) Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263:2893–2898

    Article  PubMed  CAS  Google Scholar 

  3. Hu FB, Stampfer MJ, Haffner SM, Solonen CG, Willett WC, Manson JE (2002) Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25:1129–1134

    Article  PubMed  Google Scholar 

  4. Stern MP (1995) Diabetes and cardiovascular disease: the “common soil” hypothesis. Diabetes 44:369–374

    Article  PubMed  CAS  Google Scholar 

  5. Ceriello A (2005) Postprandial hyperglycaemia and diabetic complications. Diabetes 54:1–7

    Article  PubMed  CAS  Google Scholar 

  6. Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001) Executive summary of the third report of the national cholesterol education program (NCEP). JAMA 285:2486–2497

    Article  Google Scholar 

  7. The expert committee on the Diagnosis, Classification of Diabetes Mellitus (2003) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26(suppl 1):s5–s20

    Google Scholar 

  8. Matthews D-R, Hosker J-P, Rudenski A-S, Naylor B-A, Treacher D-F, Turner R-C (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419

    Article  PubMed  CAS  Google Scholar 

  9. Maran A, Poscia A (2002) Continuous subcutaneous glucose monitoring; the GlucoDay system. Diab Nutr Metab 15:429–433

    CAS  Google Scholar 

  10. Wentholt IH, Vallebregt MA, Hart AA, Hoekstra JB, Devries JH (2005) Comparison of a needle-type and a microdialysis continuous glucose monitor in type 1 diabetic patients. Diabetes Care 28:2871–2876

    Article  PubMed  CAS  Google Scholar 

  11. De Block C, Van Gaal L, Keenoy BM, Rogiers P (2006) Intensive insulin therapy in the intensive care unit. Diabetes Care 29:1750–1756

    Article  PubMed  Google Scholar 

  12. Koh KK, Han SH, Quon MJ (2005) Inflammatory markers and the metabolic syndrome. JACC 46:1978–1985

    PubMed  CAS  Google Scholar 

  13. Borst SE (2004) The role of TNF-α in insulin resistance. Endocrine 23:177–182

    Article  PubMed  CAS  Google Scholar 

  14. Waite KJ, Floyd ZE, Arbour-Reily P, Stephens JM (2001) Interferon-γ-induced regulation of peroxisome proliferator-activated receptor γ and STATs in adipocytes. J Biol Chem 276:7062–7068

    Article  PubMed  CAS  Google Scholar 

  15. Wellen KE, Hotamisligil GS (2003) Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112:1785–1788

    PubMed  CAS  Google Scholar 

  16. Weier C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935

    Article  Google Scholar 

  17. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599

    PubMed  CAS  Google Scholar 

  18. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228

    Article  PubMed  CAS  Google Scholar 

  19. Snijder MB, Heine RJ, Seidell JC, Bouter LM, Stehouwer CDA, Nijpels G, Funahashi T, Matsuzawa Y, Shimomura I, Dekker JM (2006) Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women. Diabetes Care 29:2498–2503

    Article  PubMed  CAS  Google Scholar 

  20. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, Goldstein BJ (2002) Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 87:5662–5667

    Article  PubMed  CAS  Google Scholar 

  21. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y, Osaka CAD Study Group (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85–89

    Article  PubMed  CAS  Google Scholar 

  22. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730–1737

    Article  PubMed  CAS  Google Scholar 

  23. Kojima S, Funahashi T, Maruyoshi H, Honda O, Suguyama S, Kawano H, Soejima H, Miyamoto S, Hokamaki J, Sakamoto T, Yoshimura M, Kitagawa A, Matsuzawa Y, Ogawa H (2005) Levels of the adipocyte-derived plasma protein, adiponectin, have a close relationship with atheroma. Thromb Res 115:483–490

    Article  PubMed  CAS  Google Scholar 

  24. Pilz S, Horejsi R, Moller R, Almer G, Scharnagl H, Stojakovic T, Dimitrova R, Weihrauch G, Borkenstein M, Maerz W, Schauenstein K, Mangge H (2005) Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin. J Clin Endocrinol Metab 90:4792–4796

    Article  PubMed  CAS  Google Scholar 

  25. Lo J, Dolan SE, Kanter JR, Hemphill LC, Connelly JM, Lees RS, Grinspoon SK (2006) Effects of obesity, body composition, and adiponectin on carotid intima-media thickness in healthy women. J Clin Endocrinol Metab 91:1677–1682

    Article  PubMed  CAS  Google Scholar 

  26. Yokoyama H, Emoto M, Mori K, Araki T, Teramura M, Koyama H, Shoji T, Inaba M, Nishizawa Y (2006) Plasma adiponectin level is associated with insulin-stimulated nonoxidative glucose disposal. J Clin Endocrinol Metab 91:290–294

    Article  PubMed  CAS  Google Scholar 

  27. You T, Yang R, Lyles MF, Gong D, Nicklas BJ (2005) Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab 288:741–747

    Article  Google Scholar 

  28. Rotter V, Nagaev I, Smith U (2003) Interleukin-6 (IL-6) induces insulin resistance in 3T3–L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278:45777–45784

    Article  PubMed  CAS  Google Scholar 

  29. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y (2003) Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107:671–674

    Article  PubMed  CAS  Google Scholar 

  30. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2002) Hormonal regulation of adiponectin gene expression in 3T3–L1 adipocytes. Biochem Biophys Res Commun 290:1084–1089

    Article  PubMed  CAS  Google Scholar 

  31. Singleton JR, Smith AG, Russell JW, Feldman EL (2003) Microvascular complications of impaired glucose tolerance. Diabetes 52:2867–2873

    Article  PubMed  CAS  Google Scholar 

  32. Hirsh IB, Brownlee M (2005) Should minimal blood glucose variability become the gold standard of glycaemic control? J Diabetes Complications 19:178–181

    Article  Google Scholar 

  33. Hirsh IB (2005) Intensifying insulin therapy in patients with type 2 diabetes mellitus. Am J Med 118s5A:21s–26s

    Article  Google Scholar 

Download references

Acknowledgments

This study was supported in part by the Italian Ministero dell’Università e della Ricerca Scientifica e Tecnologica (MURST funds 60% project 2006).

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Interna, Malattie Cardiovascolari e NefroUrologiche, Facoltà di Medicina, Università di Palermo, Policlinico “P. Giaccone”, Via del Vespro, 129, 90127, Palermo, Italy

    Silvio Buscemi, Salvatore Verga, Santina Cottone, Vitalba Azzolina, Barbara Buscemi, Diana Gioia & Giovanni Cerasola

Authors
  1. Silvio Buscemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Salvatore Verga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Santina Cottone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vitalba Azzolina
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Barbara Buscemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Diana Gioia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giovanni Cerasola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvio Buscemi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buscemi, S., Verga, S., Cottone, S. et al. Glycaemic variability and inflammation in subjects with metabolic syndrome. Acta Diabetol 46, 55–61 (2009). https://doi.org/10.1007/s00592-008-0061-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-008-0061-8

Keywords

Search

Navigation